CLDN18 and gastric cancer: In diffuse‐type GC tumors, fusions involving ARHGAP26 and MUSK (CLDN18:ARHGAP26 and SNX30:MUSK) were detected in 12.0% and 4.0% (n = 25) of cases, respectively.